Latest On Harvard Bioscience, Inc (HBIO):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-04-25 18:02 EST | News | Harvard Bioscience Non-GAAP EPS of $0.06 beats by $0.02, revenue of $29.98M beats by $1.53M | N/A |  |
| 2023-04-25 18:02 EST | News | Harvard Bioscience, Inc. (HBIO) Q1 2023 Results - Earnings Call Transcript | N/A | |
| 2023-03-26 08:05 EST | News | Harvard Bioscience: Stock To Rise On Long-Term Growth And Attractive Valuation | N/A | |
| 2023-03-09 17:26 EST | News | Harvard Bioscience Non-GAAP EPS of $0.04 beats by $0.03, revenue of $28.4M misses by $1.75M | N/A | |
| 2023-03-09 17:25 EST | News | Harvard Bioscience, Inc. 2022 Q4 - Results - Earnings Call Presentation | N/A | |
About Harvard Bioscience, Inc (HBIO):
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development. It offers physiology, cell, and molecular instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. The company also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems for use with custom amplifier configurations, vivo-systems solution for in vivo recordings with mic read more...roelectrode arrays, and vitro-systems for extracellular recordings from microelectrode arrays in vitro; and offers preclinical products, systems, services, and solutions with a focus on physiologic monitoring solutions. It markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. The company primarily sells its products under Harvard Apparatus, Biochrom, Hoefer, Panlab, Warner Instruments, Hugo Sachs Elektronik, Scie-Plas, BTX, Multi Channel Systems, HEKA, DSI, Ponemah, and Buxco brand names in North America, Europe, and internationally. Harvard Bioscience, Inc. was founded in 1901 and is headquartered in Holliston, Massachusetts.
General
- Name Harvard Bioscience, Inc
- Symbol HBIO
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryMedical Instruments & Supplies
- Full Time Employees 428
- Last Split Factor1319:1000
- Last Split Date2013-11-04
- Fiscal Year EndDecember
- IPO Date2000-12-07
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryLife Sciences Tools & Services
- Gic SubIndustryLife Sciences Tools & Services
- Web URLhttp://www.harvardbioscience.com
Valuation
- Trailing PE 147.5
- Forward PE 21.98
- Price/Sales (Trailing 12 Mt.) 2.41
- Price/Book (Most Recent Quarter) 3.24
- Enterprise Value Revenue 2.82
- Enterprise Value EBITDA 88.63
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $0.26
- Next Year EPS Estimate $0.35
- Next Quarter EPS Estimate $0.05
- Profit Margin -8%
- Return on Equity -10%
- Revenue 102.1 million
- Earnings Per Share -$0.12
- Revenue Per Share $2.64
- Gross Profit 58.04 million
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 252.1 million
- EBITDA 7.85 million
- PEG Ratio 2.89
- Analyst Target Price $8.75
- Book Value Per Share $1.95
Share Statistics
- Shares Outstanding 39.83 million
- Shares Float 35.57 million
- % Held by Insiders 1273%
- % Held by Institutions 74.91%
- Shares Short 665127
- Shares Short Prior Month 636083
- Short Ratio 5.12
- Short % of Float 2%
- Short % of Shares Outstanding 2%
Technicals
- Beta 1.66
- 52 Week High $7.14
- 52 Week Low $1.42
- 50 Day Moving Average 4.9
- 200 Day Moving Average 4
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Harvard Bioscience, Inc (HBIO) Dividend Calendar:
Harvard Bioscience, Inc (HBIO) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Harvard Bioscience, Inc (HBIO) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Harvard Bioscience, Inc (HBIO) Chart:
Harvard Bioscience, Inc (HBIO) News:
Below you will find a list of latest news for Harvard Bioscience, Inc (HBIO) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Harvard Bioscience, Inc (HBIO) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest HBIO Trades:
Harvard Bioscience, Inc (HBIO) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-06 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-06 | S-8 (Securities to be offered to employees in employee benefit plans) | |
| 2020-11-05 | 8-K (Current report) | |
| 2020-11-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-10 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-10 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-05 | 8-K (Current report) | |
| 2020-08-04 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-23 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-21 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-10 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-22 | SC 13D/A (General statement of acquisition of beneficial ownership) | |
| 2020-06-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-19 | 4 (Statement of changes in beneficial ownership of securities) | |
Harvard Bioscience, Inc (HBIO) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Harvard Bioscience, Inc (HBIO). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1273%
Institutional Ownership: 7491%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-11-01 | Kenneth Fletcher Olson | Vice President | Sell | 1,863.00 | 88,598.00 | | ||
| 2020-07-18 | Michael A. Rossi | Chief Financial Officer | Buy | 23,877.00 | 157,814.00 | | ||
| 2020-07-08 | James W Green | Chief Executive Officer | Buy | 209,180.00 | 2,147,605.00 | | ||
| 2020-07-01 | BERTRAND LOY | Director | Buy | 1,300.00 | 251,126.00 | | ||
| 2020-07-01 | Susan M. Steele | Director | Buy | 1,300.00 | 38,600.00 | | ||
| 2020-07-01 | ALAN I EDRICK | Director | Buy | 4,000.00 | 99,600.00 | | ||
| 2020-06-18 | Thomas W Loewald | Director | Buy | 28,100.00 | 152,000.00 | | ||
| 2020-06-18 | Katherine A. Eade | Director | Buy | 28,100.00 | 168,915.00 | | ||
| 2020-06-18 | BERTRAND LOY | Director | Buy | 28,100.00 | 249,826.00 | | ||
| 2020-06-18 | JOHN F KENNEDY | Director | Buy | 28,100.00 | 364,359.00 | | ||
| 2020-06-18 | Susan M. Steele | Director | Buy | 28,100.00 | 37,300.00 | | ||
| 2020-06-18 | ALAN I EDRICK | Director | Buy | 28,100.00 | 95,600.00 | | ||
| 2020-06-12 | ALAN I EDRICK | Director | Buy | 20,000.00 | 2.63 | 52,500.00 | 67,500.00 | |
| 2020-06-11 | Michael A. Rossi | Chief Financial Officer | Buy | 43,092.00 | 133,937.00 | | ||
| 2020-06-11 | James W Green | Chief Executive Officer | Buy | 218,141.00 | 1,720,284.00 | | ||
| 2020-06-11 | James W Green | Chief Executive Officer | Buy | 218,141.00 | 1,938,424.00 | | ||
| 2020-06-11 | BERTRAND LOY | Director | Sell | 1,767.00 | 221,726.00 | | ||
| 2020-06-11 | JOHN F KENNEDY | Director | Sell | 3,534.00 | 336,259.00 | | ||
| 2020-06-11 | Kenneth Fletcher Olson | Vice President | Buy | 36,756.00 | 53,705.00 | | ||
| 2020-06-11 | Kenneth Fletcher Olson | Vice President | Buy | 36,756.00 | 90,461.00 | |